🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

19 recruiting trials

for Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT NCT07448727n/a1 site📍 Rome University of Rome Tor Vergata A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. NCT07791745Phase 2, Phase 31 site📍 Shanghai Taizhou Mabtech Pharmaceutical Co.,Ltd · Tests: Enlituo® + Anyouping® + PBC, Placebo-Enlituo + Anyouping® + PBC Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China NCT04857164Phase 21 site📍 Beijing Yuankai Shi · Tests: Pembrolizumab combined with Chemotherapy A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) NCT07408063Phase 21 site📍 Toronto University Health Network, Toronto · Tests: GSK5764227, Dostarlimab Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC NCT06935188Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: Dalpicilib combined with cetuximab, cetuximab Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Window of Opportunity in Preserving Laryngeal Function Trial NCT07423078Phase 21 site📍 Pittsburgh Matthew Spector · Tests: Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC NCT07807163Phase 27 sites📍 Fort Myers📍 Orlando📍 St. Petersburg Bicara Therapeutics · Tests: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. NCT06869473Phase 28 sites📍 Cagliari📍 Catania📍 Florence Gruppo Oncologico del Nord-Ovest · Tests: Cetuximab/avelumab Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC NCT06052839Phase 21 site📍 Pittsburgh Dan Zandberg · Tests: Pembrolizumab, Carboplatin, Paclitaxel H101 Plus TACE for r/m HNSCC NCT07398664Phase 21 site📍 Chengdu West China Hospital · Tests: H101, TACE Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN NCT05260671Phase 22 sites📍 Changchun📍 Shanghai Eye & ENT Hospital of Fudan University · Tests: Penpulimab combined with cetuximab A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC NCT06597565Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Gemcitabine, ACR-368 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) NCT06601335Phase 32 sites📍 Wuhan📍 Chengdu Akeso · Tests: AK117 in combination with AK112, Placebo in combination with Pembrolizumab A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma NCT06064877Phase 3112 sites📍 Gilbert📍 Tucson📍 Los Angeles AVEO Pharmaceuticals, Inc. · Tests: Ficlatuzumab, Cetuximab, Placebo A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT06769698Phase 238 sites📍 Los Angeles📍 Los Angeles📍 Orlando Regeneron Pharmaceuticals · Tests: FDC fianlimab+cemiplimab, Cemiplimab, Placebo CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma NCT07659678Phase 21 site📍 St Louis Washington University School of Medicine · Tests: 64Cu-DOTA-ECL1i PDO Based Drug Sensitive Test in R/M HNSCC NCT06686342n/a2 sites📍 Shanghai📍 Shanghai Huashan Hospital · Tests: No intervention, No Intervention: Observational Cohort FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC NCT06788990Phase 2, Phase 3231 sites📍 Birmingham📍 Phoenix📍 La Jolla Bicara Therapeutics · Tests: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy